REG - Fusion Antibodies - Result of General Meeting

Fusion AntibodiesAnnouncement

07/04/2025 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250407:nRSG9561Da&default-theme=true

RNS Number : 9561D  Fusion Antibodies PLC  07 April 2025

7 April 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Result of General Meeting

and

Total voting Rights

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that at the general meeting of the Company, held
earlier today, all resolutions were duly passed.

 

Following the passing of the resolutions, the Company has raised a total of
approximately £1.17 million pursuant to the Placing, details of which were
announced on 18 March 2025.

 

Application has been made for admission of the 8,416,020 Second Tranche
Placing Shares to trading on AIM ("Admission"). It is currently anticipated
that Admission will become effective and that dealings in the Second Tranche
Placing Shares will commence on AIM at 8.00 a.m. on 9 April 2025.

 

Total voting rights

 

On Admission, the Company will have 113,318,140 Ordinary Shares in issue, each
with one voting right.  There are no shares held in treasury. Therefore, the
Company's total number of Ordinary Shares in issue and voting rights will be
113,318,140 and this figure may be used by shareholders from Admission as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Unless otherwise defined herein, the capitalised defined terms used in this
announcement have the same meaning as those used in the Company's announcement
on 18 March 2025.

 

Navigate to our Interactive Investor hub here:
https://investorhub.fusionantibodies.com/
(https://investorhub.fusionantibodies.com/) . Engage with us by asking
questions, watching video summaries and seeing what other shareholders have to
say.

 

Enquiries:

 

 Investor questions on this announcement       Investor hub (https://investorhub.fusionantibodies.com/link/Dex1Kr)
 We encourage all investors to share questions
 on this announcement via our investor hub

 Fusion Antibodies plc                                                                        www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                           Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                                           Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                                        Tel: +44 (0) 207 186 9952

 Walbrook PR            Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                                   Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMSSDFFWEISEDL